Published in final edited form as:

Bioorg Med Chem Lett. 2015 July 15; 25(14): 2763–2767. doi:10.1016/j.bmcl.2015.05.019.

Heteroaromatic analogs of the resveratrol analog DMU-212 as potent anti-cancer agents

Narsimha Reddy Penthala, Shraddha Thakkar, and Peter A. Crooks*

Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205

Abstract

Heteroaromatic analogs of **DMU-212** (**8–15**) have been synthesized and evaluated for their anticancer activity against a panel of 60 human cancer cell lines. These novel analogs contain a *trans*-3,4,5-trimethoxystyryl moiety attached to the C2 position of indole, benzofuran, benzothiazole or benzothiophene ring (**8**, **11**, **13** and **14**, respectively) and showed potent growth inhibition in 85% of the cancer cell lines examined, with GI_{50} values $<1\ \mu\text{M}$. Interestingly, *trans*-3,4- and *trans*-3,5-dimethoxystyryl **DMU-212** analogs **9**, **10**, **12** and **15** exhibited significantly less growth inhibition than their 3,4,5-trimethoxystyryl counterparts, suggesting that the *trans*-3,4,5-trimethoxystyryl moiety is an essential structural element for the potent anticancer activity of these heterocyclic **DMU-212** analogs. Molecular modeling studies showed that the four most active compounds (**8**, **11**, **13** and **14**) all bind to the colchicine binding site on tubulin, and that their binding modes are similar to that of **DMU-212**.

Graphical abstract

Keywords

Heterocyclic resveratrol analogs; Anti-cancer activity; Indole; Benzofuran; Benothiophene; Benzothiazole

In anticancer therapy, the inhibition of microtubule function as a therapeutic strategy has been validated by utilizing the natural product resveratrol (*trans*-3,5,4'-trihydroxystilbene)

© 2015 Published by Elsevier Ltd.

*Corresponding author. Tel.: +1-501-686-6495; fax: +1-501-686-6057; pacrooks@uams.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

and its derivatives (Fig. 1; structures **I–III**) as tubulin targeting agents.^{1, 2} Resveratrol, a well-known natural polyphenolic phytoalexin compound extracted from a variety of medicinal plants and from grapes,³ is a potent anti-oxidant^{4,5} and also inhibits platelet aggregation.^{6,7} Resveratrol and its analogs have been shown to exhibit various cancer chemo-preventive properties, due to their modulation of multiple cellular processes, including apoptosis, cell cycle progression, inflammation, and angiogenesis.⁸

A series of methoxy derivatives of resveratrol have been reported as anti-cancer agents against various human cancer cell lines.^{2,9} Among these, (*E*)-3,5,4'-trimethoxystilbene (Fig. 1; structure **II**) and (*E*)-3,4,5,4'-tetramethoxystilbene (**DMU-212**, Fig. 1; structure **III**) exhibit potent anti-cancer activity and 30-to 100-fold enhanced cytotoxicity in comparison to resveratrol.¹⁰ These methoxy derivatives have been identified as microtubule-destabilizing agents endowed with anti-angiogenic and vascular-targeting properties.¹

The combretastatins, are another potent group of natural products that are inhibitors of microtubule function.^{11,12} Combretastatin analogs have been extracted from the bark of the South African tree *Combretum caffrum*, and among these natural products, combretastatin A-4 (Fig. 1; structure **IV**), a *cis*-stilbene analog, is a well-known anti-mitotic agent.¹³ The potent cytotoxicity of CA-4 against a wide variety of human cancer cell lines, including multidrug resistant cells, is due to its effect on microtubule dynamics and its affinity for the colchicine binding site on tubulin.¹⁴

A number of *trans*-CA-4 analogs structurally related to **DMU-212**, e.g. compound **V** (Fig. 1), has been found to possess potent anti-cancer activity in cells in culture at cytotoxic concentrations.^{15,16} Also, recent studies have shown that *trans*-cyanostilbene analogs that are structurally related to both **DMU-212** and *trans*-CA-4, e.g. compound **VI**, (Fig. 1), are inhibitors of tubulin polymerization with potencies comparable to that of CA-4.^{17,18}

We have previously reported on the synthesis of a wide variety of *cis*- and *trans*-substituted cyanostilbene analogs as anti-tubulin agents.¹⁷ Also, we have recently described the synthesis and potent anti-cancer activity of some *cis*- and *trans*-cyanostilbene analogs in which one of the phenyl moieties has been replaced with a heteroaromatic moiety such as benzothiophene¹⁹ and quinoline.²⁰

In the present communication, we report on the synthesis and anti-cancer activities of a variety of heteroaromatic **DMU-212** analogs (**8–15**) in which the 4-methoxyphenyl moiety in the **DMU-212** molecule has been replaced with a variety of well-known bio-active heterocyclic ring systems such as indole, benzofuran, benzothiazole and benzothiophene. The methoxy substitution pattern in the *trans*-3,4,5-trimethoxystyryl moiety in these compounds has also been varied.

A series of indole, benzo[*b*]furan, benzo[*b*]thiophen and benzo[*d*]thiazole analogs of **DMU-212** (**8–15**) were synthesized by indole-2-carbaldehyde (**1**), benzo[*b*]furan-2-carbaldehyde (**2**), benzo[*d*]thiazole-2-carbaldehyde (**3**), and benzo[*b*]thiophen-2-carbaldehyde (**4**), with a variety of triphenyl phosphonium bromide salts (**5–7**) in 5% sodium methoxide methanol at room temperature for 3–4 h (Scheme 1).

Confirmation of the structure and purity of these analogs was obtained from ^1H - and ^{13}C -NMR, and high resolution mass spectroscopic analysis. The geometry of the double bond in these molecules was established as the *trans*-configuration from ^1H -NMR studies [the *trans*-stilbene olefinic proton *J*-values range from 15–16 Hz, while the *cis*-stilbene olefinic protons have *J*-value ranging from 7.4–8.6 Hz].²¹

All the synthesized molecules were evaluated for their anti-cancer activity in a preliminary screen against a panel of 60 human cancer cell lines (NCI-60 panel) at a concentration of 10^{-5} M utilizing the procedure described by Rubinstein et al.²² In this cellular assay the growth inhibition of the test compounds is measured by determining percentage cell growth (PG) inhibition. Optical density (OD) measurements of sulforhodamine B (SRB)-derived color, just before exposing the cells to the test compound (OD_{zero}), and after 48 h exposure to the test compound (OD_{test}) or the control vehicle (OD_{ctrl}) is recorded. The growth percentage compared to control is calculated utilizing the reported formulas.²³ The NCI 60 cell panel includes different subpanels representing leukemia, non-small cell lung, colon, central nervous system, melanoma, ovary, renal, prostate, and breast cancer cell lines.

A single dose preliminary screening of the compounds was carried out on all the synthesized compounds (**8–15**) at 10^{-5} M concentration. From the preliminary screening the compounds which showed 60% or more growth inhibition in at least eight of the cell lines were further screened at five different concentrations (10^{-4}M , 10^{-5} M, 10^{-6} M, 10^{-7} M and 10^{-8} M) following 48 h of incubation. From the single dose studies, four (**9**, **10**, **12**, **15**) of the eight compounds evaluated were not considered for subsequent 5-dose studies because they only showed 60% or more growth inhibition in two to six cell lines in the panel. Compounds **8**, **11**, **13** and **14** were each evaluated in 5-dose studies designed to determine growth inhibition (GI_{50}) values, which represent the molar drug concentration required to cause 50% cell growth inhibition.

The four 3,4,5-trimethoxystyryl analogs **8**, **11**, **13** and **14** exhibited potent cytotoxicity in the 5-dose NCI-60 human cancer cell assay, and because of their structural similarity to **DMU-212**, the cytotoxic activity of these novel heterocyclic analogs likely results from their interaction with the colchicine binding site on tubulin. The growth inhibition results for the above compounds are presented in Table 1, and are summarized below.

The substitution of the *trans*-3,4,5-trimethoxystyryl moiety at the C2 position of an indole ring afforded compound **8**, which exhibited potent growth inhibition against 88% of the cancer cell lines in the panel, affording GI_{50} values ranging from 0.15 to 0.963 μM , with an average GI_{50} value of 0.90 μM for all the cell lines in the panel. This compound exhibited growth inhibition against MDA-MB-435 melanoma and UO-31 renal cancer cell lines with GI_{50} values of 0.15 and 0.17 μM , respectively (Table 1).

Incorporating the *trans*-3,4,5-trimethoxystyryl moiety at the C2 position of a benzofuran ring afforded compound **11**. This compound exhibited potent growth inhibition against 78% of the cancer cell lines in the panel, with GI_{50} values ranging from 0.078 to 0.895 μM , and an average GI_{50} value of 1.42 μM for all the cells in the panel. Compound **11** exhibited

growth inhibition against MDA-MB-435 melanoma, SR leukemia, and HOP-92 lung cancer cell lines with GI₅₀ values of 0.078, 0.094 and 0.170 μ M, respectively (Table 1).

Placing the *trans*-3,4,5-trimethoxystyryl moiety at the C2 position of a benzothiazole ring afforded compound **13**, which exhibited significant growth inhibition against 81% of the cancer cell lines in the panel with GI₅₀ values ranging from 0.024 to 0.961 μ M and an average GI₅₀ value of 1.02 μ M. This compound exhibited growth inhibition against 3 out of 6 of the cell lines in the leukemia sub-panel (GI₅₀ values 0.036–0.041 μ M); 5 out of 7 of the cell lines in the colon cancer sub-panel (GI₅₀ values 0.038–0.072 μ M); 4 out of 6 of the cell lines in the CNS cancer subpanel (GI₅₀ values of 0.070–0.095 μ M); and 6 out of 9 of the cell lines in the melanoma sub-panel (GI₅₀ values 0.024–0.072 μ M). Compound **13** also exhibited potent growth inhibition of HOP-92 lung, OVCAR-3 ovarian, and A498 renal cancer cell lines with GI₅₀ values of 0.036, 0.069, and 0.041 μ M, respectively (Table 1).

The substitution of the *trans*-3,4,5-trimethoxyphenyl moiety at the C2 position of a benzothiophene ring afforded compound **14**, which exhibited potent growth inhibition against 95% of all the cancer cell lines in the panel with GI₅₀ values ranging from 0.036 to 0.985 μ M and an average GI₅₀ value of 0.59 μ M. This compound exhibited growth inhibition against MDA-MB-435 melanoma, NCI/ADR-RES ovarian, and K-562 leukemia cancer cell lines with GI₅₀ values of 0.036, 0.070 and 0.088 μ M, respectively (Table 1).

Molecular modeling studies were performed for **DMU-212 (II)** and the four heterocyclic analogs **8**, **11**, **13** and **14** utilizing SYBYL-X 2.1 software. Binding interactions of these analogs were studied by docking them at the colchicine-binding site on tubulin. 3-D coordinates for the tubulin-colchicine complex were obtained from the RSCB protein data bank (pdb id: 4O2B). For preparation of tubulin to perform the docking calculations, the geometry of the protein molecule was optimized using energy minimization techniques after the addition of hydrogen atoms. Since no structured water molecule was present in the binding pocket, all the water molecules in the protein were deleted during the preparation of protein structure for docking calculations. Amino acid side chain bumps were fixed and terminal amino acids were charged to mimic the biological environment. Hydrogen atoms were added to the structure. The Kollman force field was applied and the protein was minimized using the Powell method and Pullman charges. Structures of compounds were initially generated in 2-D format in Chem Draw.

For generating energy-minimized structures, the 2-D structures of the molecules were converted to 3-D using Chemdraw3D and the structures saved in Mol2 format. All the structures were imported to Sybyl in the Mol2 format. In SYBYL, the TRIPOS force field was applied and 3-D structure coordinates went through a series of minimization processes. Firstly, all the structures were minimized using the BFGS method. After that, MOPAC charges were calculated for each molecule followed by steepest decedence minimization step. Each molecule was then checked for charges, bond angle, torsion angles and geometry. All the molecules were saved in one directory and prepared for docking via the ligand preparation tool. For the docking analysis using the Surflex program, a protomol was generated at the colchicine-binding site in tubulin. This protomol is the representation of the binding site that simulates the binding environment experienced by the ligand. The docking

analysis was performed using the Suflex Dock-Gemox module and lists the C-scores (consolidated scores) for each molecule (Table. 2). C-score is a measure of the goodness of fit. The C-score function combines the binding score obtained from five different scoring algorithms, namely: total score, G-score, PMF score, D-score and Chem Score. In these docking calculations, the flexibilities of the ligands were accounted for by considering 20 different conformational states and scoring each of them. Docking analysis at the colchicine-binding site demonstrated the binding mode of the resveratrol analogs. Among the tested **DMU-212** analogs, compounds **13** and **14** exhibited the strongest binding interaction at the colchicine-binding site on tubulin compared to the other two analogs. All five compounds exhibited hydrogen bonding interactions with ASN 258. Interestingly, compound **8** also exhibited hydrogen bonding with THR 353, and compound **14** exhibited two hydrogen bonding interactions with ASN 258 (Fig. 2).

Compounds **8** and **13** also exhibited hydrophobic interactions with Gln 247, and compound **14** exhibited interactions with Met 325, Gln 247, Leu 248. **DMU-212** had interactions with Lys 352, but no strong hydrophobic interactions were identified for compound **11**.

In summary, compounds **DMU-212**, **8**, **11**, **13** and **14** all exhibited similar binding interactions with tubulin at the colchicine-binding site, with compounds **13** and **14** exhibiting the most favorable interactions.

Conclusion

Novel heteroaromatic **DMU-212** analogs (**8–15**) have been synthesized and evaluated for their anti-cancer activity against a panel of 60 human cancer cell lines. Compounds containing a *trans*-3,4,5-trimethoxystyryl moiety (**8**, **11**, **13**, and **14**) showed potent growth inhibition with GI₅₀ values generally <1 μ M against most of the cancer cell lines in the panel. The removal of just one aromatic methoxy group from these compounds to afford either *trans*-3,4-dimethoxystyryl (**9**) or *trans*-3,5-dimethoxy styryl (**10**, **12**, **15**) analogs results in a decrease in anti-cancer activity, which indicates that the 3,4,5-trimethoxystyryl moiety is an essential structural element for the observed potent anti-cancer activity of these **DMU-212** analogs. Compounds **8**, **11**, **13** and **14** all exhibited significant growth inhibition against most of the human cancer cells in the 60-cell panel, and the results from the molecular modeling studies are consistent with the *in vitro* anticancer activities of these molecules being mediated via their binding to the colchicine binding site on tubulin. The above four molecules were considered as important lead compounds for further development as anti-cancer drugs.

Acknowledgements

We are grateful to NCI/NIH (Grant Number CA 140409), to the Arkansas Research Alliance (ARA) for financial support, and to the NCI Developmental Therapeutic Program (DTP) for screening data.

References and notes

1. Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stivala LA, Presta M. Mol. Pharmacol. 2005; 67:1451–1459. [PubMed: 15703378]

2. Schneider Y, Chabert P, Stutzmann J, Coelho D, Fougerousse A, Gosse F, Launay JF, Brouillard R, Raul F. *Int. J. Cancer*. 2003; 107:189–196. [PubMed: 12949793]
3. Soleas GJ, Diamandis EP, Goldberg DM. *Clin. Biochem.* 1997; 30:91–113. [PubMed: 9127691]
4. Fauconneau B, Waffo-Teguo P, Huguet F, Barrier L, Decendit A, Merillon JM. *Life Sci.* 1997; 61:2103–2110. [PubMed: 9395251]
5. Chanvitayapongs S, Draczynska-Lusiak B, Sun AY. *Neuroreport*. 1997; 8:1499–1502. [PubMed: 9172162]
6. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. *Clin. Chim. Acta.* 1995; 235:207–219. [PubMed: 7554275]
7. Bertelli AA, Giovannini L, Giannesi D, Migliori M, Bernini W, Fregoni M, Bertelli A. *Int. J. Tissue React.* 1995; 17:1–3. [PubMed: 7499059]
8. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL. *Toxicol. Appl. Pharmacol.* 2007; 224:274–283. [PubMed: 17306316]
9. Perez-Melero C, Maya AB, del Rey B, Pelaez R, Caballero E, Medarde M. *Bioorg. Med. Chem. Lett.* 2004; 14:3771–3774. [PubMed: 15203159]
10. Heynekamp JJ, Weber WM, Hunsaker LA, Gonzales AM, Orlando RA, Deck LM, Jagt DL. *J. Med. Chem.* 2006; 49:7182–7189. [PubMed: 17125270]
11. Dumontet C, Jordan MA. *Nat. Rev. Drug. Disc.* 2010; 9:790–803.
12. Lin CM, Ho HH, Pettit GR, Hamel E. *Biochem.* 1989; 28:6984–6991. [PubMed: 2819042]
13. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. *Experientia*. 1989; 45:209–211. [PubMed: 2920809]
14. McGown AT, Fox BW. *Canc. Chemo. Pharmacol.* 1990; 26:79–81.
15. Madadi NR, Crooks PA. *Lett. Drug. Des. Disc.* 2015; 12
16. Cushman M, Nagarathnam D, Gopal D, Chakraborti AK, Lin CM, Hamel E. *J. Med. Chem.* 1991; 34:2579–2588. [PubMed: 1875350]
17. Madadi NR, Zong H, Ketkar A, Zheng C, Penthala NR, Janganati V, Bommagani S, Eoff RL, Guzman ML, Crooks PA. *Med. Chem. Commun.* 2015; 6
18. Jalily PH, Hadfield JA, Hirst N, Rossington SB. *Bioorg. Med. Chem. Lett.* 2012; 22:6731–6734. [PubMed: 23010271]
19. Penthala NR, Sonar VN, Horn J, Leggas M, Yadlapalli JS, Crooks PA. *Med. Chem. Commun.* 2013; 4:1073–1078.
20. Penthala NR, Janganati V, Bommagani S, Crooks PA. *Med. Chem. Commun.* 2014; 5:886–890.
21. Alonso F, Riente P, Yus M. *European. J. Org. Chem.* 2009:6034–6042.
22. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR. *J. Natl. Cancer Inst.* 1990; 82:1113–1118. [PubMed: 2359137]
23. Madadi NR, Penthala NR, Janganati V, Crooks PA. *Bioorg. Med. Chem. Lett.* 2014; 24:601–603. [PubMed: 24361000]
24. **General procedure for the synthesis of heteroaromatic analogs of DMU-212 (8–15):** A mixture of carbaldehyde (0.001 mol), alkoxy triphenyl phosphonium bromide (0.001 mol), and sodium methoxide (2.5 gm) in methanol (50 ml) was stirred at room temperature for 3–4 h. Crushed ice was then added to afford a solid product. The crude solid was isolated by filtration and washed several times with cold methanol (3 × 5 ml). The resulting pale yellow solid was then recrystallized from methanol to afford the desired (*E*)-2-(3,4,5-trimethoxystyryl)heteroaromatic product. (*E*)-2-(3,4,5-trimethoxy styryl)-1*H*-indole (8): mp: 228–230⁰C, ¹H NMR (CDCl₃); δ 3.87 (s, 3H), 3.92 (s, 6H), 6.61 (s, 1H), 6.72 (s, 2H), 6.82–6.86 (d, *J*=16.4 Hz, 1H), 7.01–7.05 (d, *J*=16 Hz, 1H), 7.079–7.11 (t, *J*=7.2 Hz, 14.8Hz, 1H), 7.17–7.21 (t, *J*=7.2 Hz, 15.2 Hz 1H), 7.33–7.35 (d, *J*=7.6 Hz, 1H), 7.57–7.59 (d, *J*=7.6 Hz, 1H), 8.27 (brs, 1H, NH). ¹³C NMR (CDCl₃); δ 56.22, 60.89, 103.30, 103.69, 110.46, 118.53, 120.23, 120.50, 120.70, 122.85, 127.04, 127.08, 128.96, 132.57, 136.18, 136.91, 138.05, 153.46. HRMS calcd for C₁₉H₂₀NO₃, (MH⁺): 310.1438. Found 310.1435. (*E*)-2-(3,4-dimethoxystyryl)-1*H*-indole (9): mp:203–205⁰C; ¹H NMR (CDCl₃); δ 3.91 (s, 3H), 3.95 (s, 3H), 6.58 (s, 1H), 6.83–6.86 (d, *J*=10.4 Hz, 1H), 6.88 (s, 1H), 6.97 (s, 1H), 7.01–7.11 (m, 3H), 7.16–7.20 (t, *J*=7.2 and 15.2 Hz, 1H), 7.32–7.34 (d, *J*=8Hz, 1H), 7.56–7.58 (d, *J*=8Hz, 1H), 8.22 (brs, 1H, NH); ¹³C NMR (CDCl₃); δ 55.87, 55.95, 103.23, 108.40, 110.48,

111.27, 117.18, 119.82, 120.13, 120.48, 122.65, 127.00, 129.04, 129.92, 136.53, 136.84, 149.06, 149.21 ppm. HRMS calcd for $C_{18}H_{18}NO_2$, (MH^+): 280.1332. Found 280.1327. **(E)-2-(3,5-dimethoxystyryl)-1H-indole (10)**: mp:134–136 °C, 1H NMR ($CDCl_3$): δ 3.84 (s, 6H), 6.42 (s, 1H), 6.62 (s, 1H), 6.66 (s, 2H), 6.80–6.84 (d, $J=16.4$ Hz, 1H), 7.07–7.13 (m, 2H), 7.18–7.22 (t, $J=7.2$, 15.2 Hz, 1H), 7.33–7.35 (d, $J=8$ Hz, 1H), 7.58–7.60 (d, $J=7.6$ Hz, 1H), 8.25 (brs, 1H, NH), ^{13}C NMR ($CDCl_3$): δ 55.38, 100.01, 104.10, 104.42, 110.63, 119.53, 120.20, 120.66, 122.94, 127.05, 128.94, 136.10, 136.98, 138.84, 161.03 ppm. HRMS calcd for $C_{18}H_{18}NO_2$, (MH^+): 280.1332. Found 280.1341. **(E)-2-(3,4,5-trimethoxystyryl)benzo[b]furan (11)**: mp:124–126 °C, 1H NMR ($CDCl_3$): δ 3.87 (s, 3H), 3.91 (s, 6H), 6.66 (s, 1H), 6.75 (s, 2H), 6.88–6.92 (d, $J=16$ Hz, 1H), 7.20–7.26 (m, 3H), 7.44–7.46 (d, $J=8.4$ Hz, 1H), 7.51–7.53 (d, $J=7.6$ Hz, 1H) ppm; ^{13}C NMR ($CDCl_3$): δ 56.11, 60.98, 103.72, 105.04, 110.82, 115.88, 120.79, 122.90, 124.60, 129.11, 130.21, 132.25, 138.36, 153.44, 154.83, 154.94 ppm. HRMS calcd for $C_{19}H_{19}O_4$, (MH^+): 311.1278. Found 311.1273. **(E)-2-(3,5-dimethoxystyryl) benzo[b]furan (12)**: mp: 29–31 °C, 1H NMR ($CDCl_3$): δ 3.83 (s, 6H), 6.41–6.42 (d, $J=1.6$ Hz, 1H), 6.68 (s, 3H), 6.95–6.99 (d, $J=16.4$ Hz, 1H), 7.20–7.26 (m, 3H), 7.45–7.47 (d, $J=8.0$ Hz, 1H) 7.51–7.53 (d, $J=7.2$ Hz, 1H); ^{13}C NMR ($CDCl_3$): δ 55.37, 100.56, 104.71, 105.43, 110.88, 116.92, 120.84, 122.89, 124.68, 129.07, 130.23, 138.53, 154.85, 154.90, 161.01 ppm. HRMS calcd for $C_{18}H_{17}O_3$, (MH^+): 281.1172. Found 281.1170. **(E)-2-(3,4,5-trimethoxy styryl)benzo[d]thiazole (13)**: mp: 125–127 °C, 1H NMR ($CDCl_3$): δ 3.91 (s, 3H), 3.93 (s, 6H), 6.83 (s, 2H), 7.33–7.48 (m, 4H), 7.87 (s, 1H), 8.0 (s, 1H) ppm; ^{13}C NMR ($CDCl_3$): δ 56.12, 60.96, 104.47, 121.48, 122.89, 125.32, 126.33, 130.95, 134.26, 137.47, 153.5, 153.8, 166.78 ppm. HRMS calcd for $C_{18}H_{18}NO_3S$, (MH^+): 328.1002. Found 328.1007. **(E)-2-(3,4,5-trimethoxy styryl)benzo[b]thiophene (14)**: mp:154–156 °C, 1H NMR ($CDCl_3$): δ 3.87 (s, 3H), 3.92 (s, 6H), 6.73 (s, 2H), 6.89–6.93 (d, $J=16$ Hz, 1H), 7.20 (s, 1H), 7.30 (m, 2H), 7.68–7.77 (dd, $J_1=6.8$ Hz, $J_2=31.2$ Hz, 2H). ^{13}C NMR ($CDCl_3$): δ 56.14, 60.96, 103.67, 110.0, 121.79, 122.18, 123.11, 123.35, 124.51, 124.73, 130.78, 132.29, 138.81, 140.18, 142.74, 153.43 ppm. HRMS calcd for $C_{19}H_{19}O_3S$, (MH^+): 327.1049. Found 327.1047. **(E)-2-(3,5-dimethoxystyryl) benzo[b]thiophene (15)**: mp:103–105 °C, 1H NMR ($CDCl_3$): δ 3.83 (s, 6H), 6.41 (s, 1H), 6.66 (s, 2H), 6.90–6.94 (d, $J=15.6$ Hz, 1H), 7.25–7.30 (m, 4H), 7.68–7.78 (dd, $J=6.4$ Hz, 2H). ^{13}C NMR ($CDCl_3$): δ 55.73, 100.80, 104.93, 122.56, 123.16, 123.78, 123.85, 124.85, 125.14, 131.15, 138.93, 139.28, 140.50, 143.01, 161.35 ppm. HRMS calcd for $C_{18}H_{17}O_2S$, (MH^+): 297.0944. Found 297.0947.

Fig 1.
Chemical structures of potent anti-cancer agents

Fig. 2.
Molecular docking studies of compounds **13**, **14** and **DMU-212** at the colchicine binding site on tubulin

Scheme 1. Synthesis of heteroaromatic analogs of **DMU-212** (**8–15**)

Table 3

Anti-tumor activity ($GI_{50}/\mu M$)^a data for the heteroaromatic **DMU-212**^b analogs **8**, **11**, **13**, **14** from the 5-dose human cancer cell panel assay

Panel/cell line	8	11	13	14
	GI_{50}	GI_{50}	GI_{50}	GI_{50}
<u>Leukemia</u>				
CCRF-CEM	0.368	0.425	0.133	0.262
HL-60(TB)	0.347	0.356	0.037	0.246
K-562	0.393	0.267	0.041	0.088
MOLT-4	0.854	0.852	1.28	0.424
RPMI-8226	0.388	0.700	0.158	0.268
SR	0.241	0.094	0.036	0.120
<u>Lung Cancer</u>				
A549/ATCC	0.624	0.615	0.118	0.310
EKVX	na	na	na	10.3
HOP-62	0.933	0.775	0.393	0.420
HOP-92	0.201	0.170	0.036	0.322
NCI-H226	0.559	1.10	0.245	0.442
NCI-H23	0.677	3.09	0.726	0.324
NCI-H322M	nd	15.9	nd	0.649
NCI-H460	0.374	0.416	0.117	0.351
NCI-H522	0.294	0.436	0.163	0.153
<u>Colon Cancer</u>				
COLO 205	0.343	0.406	0.049	0.209
HCC-2998	2.25	0.334	2.23	0.307
HCT-116	0.534	0.522	0.072	0.246
HCT-15	0.469	0.402	0.063	0.328
HT29	0.335	0.375	0.038	0.234
KM12	0.436	0.508	0.072	0.213
SW-620	0.333	0.444	0.043	0.293
<u>CNS Cancer</u>				
SF-268	0.708	0.861	0.568	0.985
SF-295	0.311	0.356	0.070	0.442
SF-539	0.231	0.273	0.076	0.299
SNB-19	0.461	0.584	0.095	0.362
SNB-75	0.329	0.475	0.162	0.190
U251	0.442	0.668	0.088	0.338
<u>Melanoma</u>				
LOX IMVI	0.664	0.895	1.90	0.382
MALME-3M	0.388	0.413	0.072	0.826
M14	0.332	0.479	0.063	0.169

Panel/cell line	8	11	13	14
	GI ₅₀	GI ₅₀	GI ₅₀	GI ₅₀
MDA-MB-435	0.150	0.078	0.024	0.036
SK-MEL-2	0.426	0.767	0.064	0.323
SK-MEL-28	0.944	0.837	0.313	0.346
SK-MEL-5	0.305	0.345	0.047	0.267
UACC-257	nd	16.4	15.0	0.520
UACC-62	0.465	0.507	0.050	0.185
<u>Ovarian Cancer</u>				
IGROV1	0.504	0.807	0.249	0.520
OVCAR-3	0.234	0.429	0.069	0.224
OVCAR-4	0.691	1.15	1.81	0.553
OVCAR-5	0.963	2.94	0.939	0.547
OVCAR-8	0.587	2.05	0.396	0.352
NCI/ADR-RES	0.365	0.511	0.106	0.070
SK-OV-3	0.676	0.656	0.165	0.263
<u>Renal Cancer</u>				
786-0	0.802	0.850	1.32	0.445
A498	0.281	0.408	0.041	0.213
ACHN	0.620	0.863	1.22	0.810
CAKI-1	0.382	0.580	0.143	4.35
RXF 393	0.275	0.329	0.142	0.168
SN12C	1.64	4.09	9.37	0.666
TK-10	21.6	8.46	11.1	0.566
UO-31	0.172	1.15	0.376	0.513
<u>Prostate Cancer</u>				
PC-3	0.381	0.524	0.138	0.276
DU-145	0.384	1.86	0.272	0.402
<u>Breast Cancer</u>				
MCF7	0.395	0.373	0.313	0.285
MDA-MB-231/ATCC	1.30	1.17	0.713	0.450
HS 578T	0.257	0.499	0.171	0.275
BT-549	0.938	1.09	3.72	0.326
T-47D	nd	0.693	0.961	nd
MDA-MB-468	0.285	0.662	0.825	na

na: Not analyzed; nd: not determined;

^aGI₅₀: concentration of drug resulting in a 50% reduction in net cell growth, as compared to cell numbers on day 0.

^bFive dose NCI cancer cell screening data for **DMU-212** has been previously reported.¹⁵

Table 2Docking results for **DMU-212**, **8**, **11**, **13**, and **14** at the colchicine-binding site on tubulin

Comp.	No. of H-bonds	Maximum C-score	No. of positions with maximum C-score/20
DMU-212	1	4	1
8	2	4	2
11	1	4	2
13	1	5	1
14	2	5	2